LENZ Therapeutics (LENZ) risk factors, FY2024 10-K

Risks Related to Our Limited Operating History, Development and Commercialization of Our Product Candidates

1. 01Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and ability to achieve and maintain profitability
2. 02our business will be materially harmed. We currently generate no revenue from sales of any products and may never generate revenue or be profitable
3. 03Our current product candidate, LNZ100, is based on an active pharmaceutical ingredient (“API”) that has been previously approved and marketed outside of the United States, which exposes us to additional risks
4. 04Even if LNZ100 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, and the market opportunity for these products, if approved, may be smaller than we estimate
5. 05If we experience delays or difficulties in the enrollment and/or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
6. 06Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay
7. 07LNZ100 may not demonstrate sufficient additional clinical benefits to ECPs, patients or payors to justify a higher price compared to using glasses, which are potentially just a one-time purchase
8. 08We may need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all
9. 09If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, if approved
10. 10A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
11. 11These and other risks associated with our international operations or those of any applicable international partners may materially adversely affect our ability to attain or maintain profitable operations

Risks Related to Our Intellectual Property

1. 12Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
2. 13Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
3. 14We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products
4. 15We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization of LNZ100 and any future product candidate
5. 16Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
6. 17Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
7. 18We may not be able to protect our intellectual property rights throughout the world, which could impair our business
8. 19If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
9. 20We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property
10. 21If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
11. 22Intellectual property rights do not necessarily address all potential threats to our competitive advantage
12. 23Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products
13. 24If we fail to comply with our obligations under any license, collaboration or other agreements, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates
14. 25agreements. Any of these events could adversely affect our business, financial condition, results of operations, and prospects
15. 26In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities
16. 27We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties

Risks Related to Our Regulatory Approval and Other Legal Compliance Matters

1. 28Additional time may be required to develop and obtain regulatory approval for LNZ100 because we expect it will be regulated as a drug-device combination product
2. 29Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
3. 30We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
4. 31company and the pharmaceutical industry as a whole is unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved
5. 32Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 33If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
7. 34We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations and can face serious consequences for violations
8. 35Restrictive laws and regulations govern the collection, use, transfer, and other processing of personal information

Risks Related to Our Reliance on Third Parties

1. 36future dependence upon others for the manufacture of LNZ100 may adversely affect our future profit margins and our ability to commercialize LNZ100, if approved, on a timely and competitive basis
2. 37The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of LNZ100 for patients, if approved, could be delayed or prevented
3. 38We entered into a collaboration agreement with CORXEL and depend on CORXEL to develop and commercialize its products within Greater China. We have limited control over how CORXEL will conduct development and commercialization activities for LNZ100 or LNZ101

Risks Related to Our Business Operations

1. 39Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees
2. 40If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks
3. 41We expect to significantly expand our organization, including building sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
4. 42We could be subject to securities class action litigation, which is expensive and could divert management attention

Risks Related to Our Common Stock

1. 43An active trading market for our common stock may never develop or be sustained
2. 44The market price of our common stock is expected to be volatile, and the market price of the common stock may drop
3. 45On April 9, 2024, we filed a registration statement on Form S-1 to register the offer and sale of 1,297,411 shares of common stock issued in the March 2024 PIPE Financing, and on April 10, 2024, that registration statement was declared effective by the SEC
4. 46Our board of directors is authorized to issue and designate shares of our convertible preferred stock in additional series without stockholder approval
5. 47We will continue to be an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors
6. 48If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired
7. 49Our certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management
8. 50Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us
9. 51Transfers of our securities utilizing Rule 144 of the Securities Act may be limited
10. 52The disposal of Graphite’s historical assets and operations in connection with the Merger made us subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we will be subject to more stringent reporting requirements, offering limitations, and resale restrictions
11. 53If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline
12. 54We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition
13. 55Our ability to use net operating loss carryforwards and other tax attributes may be limited, including those obtained as a result of the Merger
14. 56Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations, or cash flows